Literature DB >> 8636245

Acromegaly: what constitutes optimal therapy?

L A Frohman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636245     DOI: 10.1210/jcem.81.2.8636245

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  8 in total

1.  Acromegaly: are new tests needed?

Authors:  Anna Spada
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 2.  Medical management of growth hormone-secreting pituitary adenomas.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Early lung function abnormalities in acromegaly.

Authors:  A Benfante; A Ciresi; M Bellia; F Cannizzaro; V Bellia; C Giordano; N Scichilone
Journal:  Lung       Date:  2015-03-11       Impact factor: 2.584

4.  Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.

Authors:  M Suliman; R Jenkins; R Ross; T Powell; R Battersby; D R Cullen
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

5.  Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

Authors:  Marina Gradiser; Martina Matovinovic; Milan Vrkljan
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

6.  Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

Authors:  P Chanson; A Leselbaum; J Blumberg; G Schaison
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

Review 7.  A risk-benefit assessment of octreotide in the treatment of acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

8.  PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.